All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Capivasertib Plus Paclitaxel Misses OS End Points in Advanced Triple-Negative Breast Cancer

June 18th 2024

Capivasertib plus paclitaxel did not improve OS vs paclitaxel in locally advanced or metastatic TNBC or patients with PIK3CA, AKT1, or PTEN alterations.

RAMP 301 Aims to Solidify Avutometinib Plus Defactinib in Recurrent LGSOC

June 18th 2024

As investigators continue efforts to improve outcomes for patients with low-grade serous ovarian cancer, they are expanding investigations beyond chemotherapy.

Patients With CLL Place the Most Value on Treatments That Prolong PFS

June 18th 2024

A survey of adult patients with chronic lymphocytic leukemia demonstrated that respondents preferred therapies that increased PFS vs other attributes.

Frontline Acalabrutinib/BR Regimen Significantly Improves PFS in Mantle Cell Lymphoma

June 17th 2024

Frontline treatment with acalabrutinib and bendamustine/rituximab (BR) improved PFS over BR alone in older patients with mantle cell lymphoma.

Sonrotoclax Plus Zanubrutinib Is Safe, Efficacious in Relapsed/Refractory CLL/SLL

June 17th 2024

The combination of sonrotoclax and zanubrutinib had a tolerable safety profile and led to durable responses in relapsed/refractory CLL/SLL.

FDA Places Partial Clinical Hold on Phase 1 Trial of YL202 in Advanced NSCLC and Breast Cancer

June 17th 2024

The FDA placed a partial clinical hold on a phase 1 trial evaluating YL202 in select patients with advanced non–small cell lung cancer or breast cancer.

Linvoseltamab Elicits Deep, Durable Responses in R/R Multiple Myeloma

June 17th 2024

Linvoseltamab induced durable responses in patients with relapsed or refractory multiple myeloma, including those with high-risk features.

Prospective Analysis Highlights Patterns of Progression to Myelofibrosis Following Essential Thrombocythemia Diagnosis

June 17th 2024

Patients with essential thrombocythemia who progressed to myelofibrosis had longer duration of disease, higher white blood cell counts, and lower hemoglobin levels at enrollment.

FDA Approves Pembrolizumab Plus Chemotherapy for Advanced/Recurrent Endometrial Carcinoma

June 17th 2024

The FDA has approved pembrolizumab plus carboplatin and paclitaxel, followed by pembrolizumab alone, for primary advanced or recurrent endometrial carcinoma.

Acalabrutinib and Zanubrutinib Both Best Ibrutinib in Real-World Safety and Efficacy CLL/SLL Outcomes

June 17th 2024

Acalabrutinib and zanubrutinib monotherapy displayed better real-world safety and efficacy in chronic lymphocytic leukemia and small lymphocytic lymphoma compared with ibrutinib.

Lower Tumor Burden Associated With Improved ORR With Liso-Cel in R/R CLL/SLL

June 17th 2024

Lower disease burden improves response to liso-cel treatment in CLL/SLL, reports TRANSCEND CLL 004 trial.

FDA Approval Sought for Subcutaneous Amivantamab in EGFR+ NSCLC

June 17th 2024

A BLA is seeking the approval of subcutaneous amivantamab for all currently approved indications of the IV formulation in EGFR+ NSCLC.

UCSF Health Reaches 15,000 Robotic Surgeries

June 17th 2024

The milestone robotic procedure is a complex gastrointestinal surgery.

Roswell Park-Led Research Shows Muscle & Fat Strongly Linked to Survival in Epithelial Ovarian Cancer

June 16th 2024

Roswell Park researchers and partners shed light on how body composition at the time of diagnosis relates to mortality in epithelial ovarian cancer.

CD19-Directed CAR T-Cell Therapy Demonstrates Clinical Efficacy in Richter Transformation

June 16th 2024

Treatment with FDA-approved CAR T-cell therapies for non-Hodgkin lymphoma was efficacious and feasible in patients with Richter transformation.

New Research Platform Assesses Brain Cancer Mutations During Surgery

June 15th 2024

Mayo Clinic researchers report on a new surgical platform used during surgery that informs decision-making about tumor treatment within minutes.

Zanubrutinib Associated With Cost Savings and QALY Benefits vs Acalabrutinib in B-Cell Malignancies

June 15th 2024

Zanubrutinib was associated with improved cost savings and quality-adjusted life year benefits vs acalabrutinib in B-cell malignancies.

ATRA/ATO Regimen Improves EFS in Newly Diagnosed, High-risk APL

June 15th 2024

Arsenic trioxide plus all-trans retinoic acid & idarubicin improved EFS vs standard ATRA and anthracycline-based chemotherapy in high-risk APL.

Glofitamab Plus Gemcitabine/Oxaliplatin Shows Survival Benefit in Transplant-Ineligible R/R DLBCL

June 15th 2024

Adding fixed-duration glofitamab-gxbm (Columvi) to gemcitabine and oxaliplatin led to a statistically significant and clinically meaningful improvement in survival vs rituximab (Rituxan) plus gemcitabine/oxaliplatin in patients with relapsed/refractory diffuse large B-cell lymphoma not eligible for autologous stem cell transplant.

Zanubrutinib Plus Obinutuzumab/Venetoclax Is Safe, Elicits Responses in Older Patients With Untreated MCL

June 15th 2024

The combination of zanubrutinib, obinutuzumab, and venetoclax was safe and well-tolerated in older patients with untreated mantle cell lymphoma.